Quoin Q3 Net Loss Rises to $4.9 Million; Cash Totals $33.2 Million
Quoin Pharmaceuticals reported a net loss of $4.9 million for the quarter ended September 30, 2026, up from $3.9 million a year earlier, and a nine-month net loss of $15.2 million versus $11.5 million. The company said it had about $33.2 million in cash, cash equivalents and marketable securities at quarter end, and it highlighted positive interim Netherton Syndrome data and new regulatory designations. Shareholders see a wider loss alongside clinical and regulatory progress.
Key points
- Q3 2026 net loss was approximately $4.9 million, compared with approximately $3.9 million in Q3 2025.
- Nine-month 2026 net loss was approximately $15.2 million, compared with approximately $11.5 million for the same period in 2025.
- Cash, cash equivalents and marketable securities were approximately $33.2 million as of September 30, 2026.
- Up to $50.0 million private placement was announced August 28, 2026, with approximately $30.8 million in initial upfront funding.
The filing
Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.